Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network

OBJECTIVES: Pazopanib received US Food and Drug Administration approval in 2009 for advanced renal cell carcinoma. During clinical development, liver chemistry abnormalities and adverse hepatic events were observed, leading to a boxed warning for hepatotoxicity and detailed label prescriber guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shantakumar, Sumitra, Nordstrom, Beth L., Hall, Susan A., Djousse, Luc, van Herk-Sukel, Myrthe P.P., Fraeman, Kathy H., Gagnon, David R., Chagin, Karen, Nelson, Jeanenne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407814/
https://www.ncbi.nlm.nih.gov/pubmed/28430700
http://dx.doi.org/10.1097/PTS.0000000000000332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407814/
https://www.ncbi.nlm.nih.gov/pubmed/28430700
http://dx.doi.org/10.1097/PTS.0000000000000332

Ejemplares similares